focus -WSS

focus

author：fashion 2025-10-01 00:46:32 - browse：6

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Chamber of Commerce, DOJ clash in court over drug prices

WSS

Radiology is caught between AI's potential and concern for patients

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Information blocking fines are now fair game in health care

House panel takes first step toward fixing drug shortages

Assistant physicians can help address the primary care shortage

'A game

hotspot

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Congenital heart disease patients face new threat of heart failure

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

White House Covid adviser calls on docs to combat misinformation

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Medicare proposal to cover medical devices draws a mixed reaction

CMS should re

Anesthesiologist group: stop taking Ozempic before surgery

Supreme Court wrestles with OxyContin maker's bankruptcy deal

hotspot

In diabetes hearing, Sanders takes on a new foe: food makers

FDA panel to weigh safety of artificial wombs for preterm births

Neurocrine congenital adrenal hyperplasia trial succeeds

Congenital heart disease patients face new threat of heart failure

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

What PEPFAR has meant on the ground in Ukraine

knowledge

focus

explore

focus